toujeo

Showing 7 posts of 7 posts found.

Sanofi secures expanded European approval for Toujeo in type 1 diabetes

January 10, 2020
Medical Communications, Sales and Marketing EU, Sanofi, pharma, toujeo

Sanofi has revealed that the European Commission has expanded the existing label for Toujeo (insulin glargine 300 units/mL) to include …

Promising Phase 3 data for Sanofi’s Toujeo secures CHMP recommendation of label expansion in type 1 diabetes

November 4, 2019
Research and Development, Sales and Marketing EU, Sanofi, Type 1 diabetes, diabetes, pharma, toujeo

Sanofi took the opportunity at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts to …

Sanofi’s Toujeo proves non-inferior to insulin degludec in type 2 diabetes

June 26, 2018
Manufacturing and Production, Research and Development, Sales and Marketing American Diabetes Association, Sanofi, diabetes, insulin glargine, pharma, toujeo, type 2 diabetes

Sanofi took the opportunity at the American Diabetes Association (ADA) 78th Scientific Sessions in Florida to unveil new data on …

Toujeo pen

Sanofi launches new insulin Toujeo in the UK

August 4, 2015
Manufacturing and Production, Sales and Marketing Lantus, Sanofi, biosimilars, diabetes, hypoglycaemia, insulin, toujeo

Sanofi’s new insulin Toujeo is now available for clinicians to prescribe in the UK. The French firm is looking to …

Sanofi Paris HQ

Sanofi’s Toujeo approved in Japan

July 3, 2015
Manufacturing and Production, Sales and Marketing Japan, Lantus Lantus XR, Sanofi, diabetes, toujeo, type diabetes

The Ministry of Health, Labor and Welfare in Japan has given Sanofi a marketing authorisation for the diabetes drug the …

Sanofi image

Sanofi rules out Toujeo discount in diabetes

April 14, 2015
Sales and Marketing 100 U/mL, Boehringer, Lantus, insulin glargine [rDNA origin] injection, lilly, toujeo

Sanofi has revealed that it will not discount its new insulin Toujeo more than its current blockbuster Lantus, despite lacking …

Sanofi image

Type 1 diabetes market value to double by 2023

March 19, 2015
Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1

The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …

Latest content